Repercussions Of A Merger: TRU-015 Potentially Up For Grabs
This article was originally published in The Pink Sheet Daily
Executive Summary
Change-of-control provision may return Phase IIb rheumatoid arthritis program to biotech developer. Would Pfizer pay (again) to be the partner?
You may also be interested in...
Pfizer Backs Out Of Cardiovascular R&D
Drug giant exits obesity, anemia, disease-modifying osteoarthritis and more.
Wyeth Pulls Plug On Trubion Candidate In NHL
Firms forge ahead with rheumatoid arthritis program.
Change of Control: Why Getting it Right Matters Even More
Private biotechs' growing dependence on an M&A exit and the more lively acquisition activity throughout the sector means change of control provisions are being far more heavily negotiated than in the past, and it's critical to understand how far-reaching these provisions could be for biotechs hoping for successful exits.